

Management of HIV/TB Co-Infection in Adults

Patrick Lee, MD, DTM&H
Divya Mallampati, MSII

Objectives

- Explain why TB is such a serious disease for HIV-positive patients.
- Understand the human rights approach to comprehensive TB/HIV care in practice.
- Learn to manage suspected TB in ambulatory HIV-positive patients who do not have danger signs.
- Learn to manage suspected TB in seriously ill HIV-positive patients.

HIV/TB Co-infection

- People with HIV more likely to get TB. Their disease will be more severe and the diagnosis more difficult to achieve because their TB presentation is often extrapulmonary or atypical.
- TB can often worsen HIV/AIDS, leading to more rapid decline in health and death.

Test all HIV patients and anyone with a cough lasting more than 3 weeks!

Screening for TB

- Symptoms:
 - Cough > 3 weeks
 - Fever, night sweats, weight loss
 - Close contact with TB patient
- Danger signs:
 - Temp > 39 C
 - HR > 120
 - RR > 30
 - Needs assistance walking

Integrated Treatment

- Anti-TB medication
- ART
- Cotrimoxazole
- Adherence support (DOT)
- Nutritional and social support
- Active case-finding
- Patient education

Introducing Meds in New Co-Infection

- Day 0: Start *anti-TB* treatment
- Day 7: Start *cotrimoxazole* prophylaxis
- Day 14: Start *ART*

Staging the introduction of the different medications helps avoid confusion from overlapping side effects.

Anti-TB Treatment Regimens

Figure removed due to copyright, showing treatment regimens for different patient categories: new case, previously treated case, not responding to treatment.

Multi-Drug Resistant(MDR) TB

- MDR TB: resistant to isoniazid (H) and rifampicin (R)
 - XDR TB: resistant to H, R, and two 2nd line drugs
- More difficult and expensive to treat
- Always fatal if not treated
- Mainly caused by lack of adherence to treatment (ineffective TB programs)

ART regimens chart for treatment-naïve adults		
<i>Recommendation</i>	<i>ART Regimen</i>	<i>Dosage</i>
Preferred regimen	TDF / 3TC or FTC / NVP Tenofovir / Lamivudine or Emtricitabine / Nevirapine	<p><i>Initial phase (first 15 days):</i></p> <ul style="list-style-type: none"> (TDF 300mg + 3TC 300mg) 1 tab 1x/day <u>and</u> NVP 200mg 1tab 1x/day OR TDF 300mg 1 tab 1x/day <u>and</u> FTC 300mg 1 tab 1x/day <u>and</u> NVP 200mg 1tab 1x/day <p><i>Maintenance phase (after 15 days):</i></p> <ul style="list-style-type: none"> (TDF 300mg + 3TC 300mg) 1 tab 1x/day <u>and</u> NVP 200mg 1tab 2x/day OR TDF 300mg 1 tab 1x/day <u>and</u> FTC 300mg 1 tab 1x/day <u>and</u> NVP 200mg 1tab 2x/day
<p>Alternatives:</p> <p>If NVP contra- indicated (ex: concomitant anti-TB treatment or allergy)</p> <p>If TDF contra- indicated (ex: renal insufficiency)</p>	<p>TDF / 3TC or FTC / EFV Tenofovir / Lamivudine or Emtricitabine / Efavirenz</p> <p>ABC / 3TC / NVP Abacavir / Lamivudine / Nevirapine</p> <p>ABC / 3TC / EFV Abacavir / Lamivudine / Efavirenz</p>	<ul style="list-style-type: none"> (TDF 300mg + 3TC 300mg) 1 tab 1x/day <u>and</u> EFV 600mg 1tab 1x/day OR TDF 300mg 1 tab 1x/day <u>and</u> FTC 300mg 1 tab 1x/day <u>and</u> EFV 200mg 1tab 1x/day <p><i>Initial phase (first 15 days):</i></p> <ul style="list-style-type: none"> ABC 600mg <u>and</u> 3TC 300mg 1 tab 1x/day <u>and</u> NVP 200mg 1tab 1x/day <p><i>Maintenance phase (after 15 days):</i></p> <ul style="list-style-type: none"> ABC 600mg <u>and</u> 3TC 300mg 1 tab 1x/day <u>and</u> NVP 200mg 1tab 2x/day ABC 600mg + 3TC 300mg 1 tab 1x/day <u>and</u> EFV 600mg 1tab 1x/day

Patrick Lee personal file, no permission needed

Cotrimoxazole Prophylaxis

- Criteria for starting cotrimoxazole prophylaxis
 - CD4 cell count below 350 cells/mm³
 - WHO Clinical Stage 3 or 4
 - Stage 3 = symptomatic HIV infection
 - Stage 4 = progression from HIV to AIDS
- Dosage prescribed
 - 960mg orally once a day
- Discontinuation
 - Only if CD4 count is above 350 cells/mm³ > 6 months after starting ART

Accompaniment and Support

- Directly Observed Therapy (DOT) is the process of distributing therapy and watching patients take their medications
 - Improves adherence
 - Prevents drug resistance
 - Increases chances of being cured
- CHWs can also monitor the status of patients: other health issues, nutrition, economic problems, etc.
- Active case-finding is an important part of maintaining the health of the community and surveillance.

Patient Education:

5 Key Messages

- Adherence
 - Take meds **EVERYDAY** and complete the **FULL** course
- Monitor symptoms
 - Tell **CHW** about any serious side effects
- Case-finding
 - Bring family and close contacts to clinic for testing
- Get/obtain nutritional and social support
- Family planning

Infection Control

- Teach TB patient etiquette
 - Patients should cover mouth when coughing or sneezing
- Isolate TB patients
- Wear N95 mask
- Good treatment
 - Assure adherence and provide nutritional and social support

Extrapulmonary TB

- TB outside of the actual lungs
- Smear-negative
- Generally non-contagious
- More common in immunocompromised patients
- Suspect extrapulmonary TB if
 - Clinical suspicion of TB
 - Negative sputum smears and CXR
 - No response to oral antibiotics
 - Second negative set of sputum smears

Image removed due to copyright, showing various sites of extrapulmonary TB infection